


Supplementary Information for

Epigenetic priming with decitabine augments the therapeutic effect of cisplatin on triple-negative breast cancer cells through induction of proapoptotic factor NOXA

Nakajima et al.

Supplementary Figure 1

(Figure1e)







Figure S1. Raw data of Immunoblot from Fig 1.

Supplementary Figure 2

(Figure3d)







Figure S2. Raw data of Immunoblot from Fig 3.

Supplementary Figure 3

(Figure4c)



(Figure4f)





Figure S3. Raw data of Immunoblot from Fig 4.

Supplementary Figure 4

(Figure5b)








Figure S4. Raw data of Immunoblot from Fig 5.

Supplementary Figure 5

(Figure6a)



(Figure6b)






Figure S5. Raw data of Immunoblot from Fig 6.

Supplementary Figure 6




Figure S6. KLF4 did no effect on the induction of NOXA by decitabine. MDA-MB-468 cells were infected with shRNAs (sh-control and sh-KLF4). Cells were exposed to 500 nM decitabine. After treatment for 72 h, mRNA levels were measured by quantitative real-time PCR (qPCR). Error bars indicate SD (n=3).

Supplementary Figure 7

(Figure8c)




Figure S7. Raw data of Immunoblot from Fig 8.